Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-cash Items (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Non-cash Items for 5 consecutive years, with $213.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 242.18% year-over-year to $213.3 million, compared with a TTM value of $213.3 million through Dec 2025, up 242.18%, and an annual FY2025 reading of $213.3 million, up 2679.04% over the prior year.
  • Non-cash Items was $213.3 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $6.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $213.3 million in Q4 2025 and bottomed at $4.4 million in Q1 2021.
  • Average Non-cash Items over 5 years is $23.6 million, with a median of $7.1 million recorded in 2023.
  • Peak annual rise in Non-cash Items hit 242.18% in 2025, while the deepest fall reached 12.67% in 2025.
  • Year by year, Non-cash Items stood at $14.9 million in 2021, then soared by 118.33% to $32.6 million in 2022, then soared by 67.47% to $54.7 million in 2023, then increased by 14.05% to $62.3 million in 2024, then soared by 242.18% to $213.3 million in 2025.
  • Business Quant data shows Non-cash Items for KNSA at $213.3 million in Q4 2025, $6.6 million in Q3 2025, and $7.2 million in Q2 2025.